Leading global medical technology provider operating in three primary segments: Cardiovascular ($14B), Neuroscience ($10.2B), and Medical Surgical ($8.8B). The company has global exposure with approximately 50% of revenue generated outside the U.S.

Enormous scale and product breadth across therapeutic and diagnostic markets in >150 countries. High switching costs for customers (health care providers) due to deep integration of proprietary platforms and specialized training.

• Portfolio Restructuring: Completed the partial IPO/carve-out of its Diabetes care division (MiniMed, MMED) in March 2026, retaining 90% ownership. This unlocks value and focuses Medtronic's resources on core, higher-margin segments.
• Acquisitions: Completed the $550M acquisition of Scientia Vascular in June 2026 to enhance its neurovascular portfolio (guidewires/catheters for complex cerebral navigation).
• Pipeline Progress: Actively advancing FDA submissions for the Hugo robotic-assisted surgery system and receiving FDA clearance for the Stealth AXiS Surgical System.

• Geopolitical & Procurement: Regulatory and anti-corruption campaigns in China (approx. 10% of sales) coupled with volume-based procurement policies are causing steep price cuts.
• Operational Drag: Ongoing margin pressures from raw material inflation, supply chain constraints, and litigation verdicts (Santa Rosa facility verdict).